Nvidia and QIA-Backed Iambic Therapeutics Files for US IPO

Key Facts

1Drug developer Iambic Therapeutics filed for a US initial public offering on Monday.

2The company is backed by chip giant Nvidia and the Qatar Investment Authority (QIA).

Reflecting the growing intersection of artificial intelligence and healthcare, drug developer Iambic Therapeutics filed for a US initial public offering on Monday. The company is seeking to capitalize on a busy fall window for biotech listings, leveraging its high-profile backing from industry leaders. Iambic Therapeutics is notably supported by chip giant Nvidia and the Qatar Investment Authority (QIA), signaling strong institutional confidence.

Per market data, Nvidia's involvement highlights its expanding influence in AI-driven healthcare, with NVDA shares closing at $227.075 (close September 21, 2026). In the broader semiconductor and tech landscape, peer prices show AMD at $559.82 and INTC at $108.6 (close September 18, 2026), while TSM stood at $441.765 (close September 21, 2026). These valuations provide context for the market environment facing new high-tech issuers.

Investors will be watching for the specific pricing and share count of the Iambic IPO, while monitoring NVDA price action near its recent daily high of $227.1 (close September 21, 2026). With no major sector-specific catalysts in the immediate upcoming calendar, the primary focus remains on the broader appetite for biotech and AI-linked equity offerings.